Adlai Nortye receives approval to begin trial in Australia
SINGAPORE and NORTH BRUNSWICK, N.J. (NASDAQ:ANL) received approval from Australia’s Human Research Ethics Committee to begin a phase I clinical trial of AN4035, an antibody drug conjugate for treating certain solid tumors, according to a press release statement.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
SINGAPORE and NORTH BRUNSWICK, N.J. (NASDAQ:ANL) received approval from Australia’s Human Research Ethics Committee to begin a phase I clinical trial of AN4035, an antibody drug conjugate for treating certain solid tumors, according to a press release statement. The company submitted a Clinical Trial Notification to Australia’s Therapeutic Goods Administration and obtained the necessary ethics committee clearance. AN4035 targets CEACAM5 and delivers a pan-RAS(ON) inhibitor payload designed to treat CEACAM5-enriched RAS-addicted solid tumors.
Read the full report at Investing.com · Company News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- SINGAPORE and NORTH BRUNSWICK, N.J. (NASDAQ:ANL) received approval from Australia’s Human Research Ethics Committee to begin a phase I clinical trial of AN4035, an antibody drug conjugate for treating certain solid tumors, according to a press release statement.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- just now ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Adlai Nortye receives approval to begin trial in Australia
Sources1TypeCoverageInvesting.com · Company News